Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

PYC Therapeutics Limited ( (AU:PYC)) has issued an announcement. PYC Therapeutics Limited has issued 2.5 million unlisted employee options under its employee incentive scheme, effective 5 January 2026 ...

PYC Therapeutics Limited has lodged its Appendix 4D and interim financial statements for the half-year ended 31 December 2025 with the ASX. The release signals continued progression of the company’s ...

The secondary aim of the trial is to assess the drug’s efficacy when the trial extends to polycystic kidney disease patients in the second half of this year. Credit: SewCreamStudio / Shutterstock. · ...

PYC Therapeutics Limited (AU:PYC) has released an update. PYC Therapeutics Limited has announced a significant breakthrough in treating Phelan-McDermid Syndrome (PMS), a rare neurodevelopmental ...

The last three months have been tough on PYC Therapeutics Limited (ASX:PYC) shareholders, who have seen the share price decline a rather worrying 36%. But that doesn't change the fact that the returns ...

PYC Therapeutics Limited has announced the issuance of 1,200,000 unlisted options, set to expire in November 2028, with each option exercisable at $3.00. This move is part of an employee incentive ...

PYC Therapeutics (ASX: PYC) presented its Q2 2025 investor webinar on May 30, outlining progress across its genetic medicine pipeline while facing continued market skepticism. The company’s stock ...